Saturday 17 October 2026
Export QURE’s income statement to Excel — free account
uniQure N.V.
QURE Healthcare Biotechnology
uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.0%, EPS fell 76.8%, free cash flow grew 27.7% and total debt fell 3.27%, each against the same quarter a year earlier.
21.72
0.80
−3.55%
Follow QURE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
163.41 | 56.70 | 85.48 | 216.85 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(106.77) | (26.82) | (17.74) | (208.28) | |
P/B ratio |
9.42 | 6.87 | 6.92 | 14.93 | |
Price to Tangible BV |
12.85 | 18.81 | 13.66 | 26.42 | |
EV/Sales |
123.14 | 27.50 | 50.40 | 176.59 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(14.30) | (2.89) | (4.56) | (18.15) | |
EV/FCF |
(14.05) | (2.85) | (4.49) | (17.85) | |
Quick Ratio |
9.79 | 9.97 | 9.99 | 6.94 | |
Current Ratio |
10.01 | 10.40 | 10.43 | 7.12 | |
Net Debt/EBITDA |
16.07 | 12.55 | 11.90 | 13.55 | |
Debt/Assets |
5.09% | 6.41% | 6.02% | 5.84% | |
Debt/Equity |
0.15 | 0.33 | 0.25 | 0.23 | |
Asset Turnover |
0.02 | 0.03 | 0.02 | 0.02 | |
Operating CF/Net income |
0.35 | 0.71 | 2.09 | 0.20 | |
Capex/Depreciation |
(0.10) | (0.05) | (0.04) | 0.02 | |
Interest Coverage |
(3.63) | (3.26) | (3.51) | (3.05) | |
Research and Development Expense of Revenue |
581.48% | 819.09% | 624.71% | 928.56% | |
Selling, General and Administrative Expense of Revenue |
297.33% | 563.39% | 388.11% | 525.21% | |
Intangible Assets out of Total Assets |
0.09 | 0.12 | 0.12 | 0.11 | |
Share Based Compensation of Revenue |
85.88% | 142.90% | 83.75% | 95.16% | |
Graham Net Nets |
0.06 | (0.01) | 0.02 | 0.02 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(8.71%) | (21.28%) | (14.42%) | (7.52%) | |
Free Cash Flow Yield |
(5.36%) | (17.04%) | (13.13%) | (4.56%) | |
Revenue per Share |
0.09 | 0.06 | 0.10 | 0.06 | |
Operating CF per Share |
(0.43) | (0.61) | (1.35) | (0.28) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.44) | (0.61) | (1.35) | (0.28) | |
Cash per Share |
12.23 | 9.35 | 10.83 | 11.86 | |
Shareholders Equity per Share |
4.89 | 2.38 | 3.46 | 3.91 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.89 | 2.38 | 3.46 | 3.91 | |
Free Cash Flow |
(29.05) | (38.38) | (77.69) | (16.33) | |
Working Capital |
750.92 | 556.55 | 593.07 | 615.56 | |
Capital Expenditures |
(0.47) | (0.14) | (0.12) | 0.07 | |
Net Current Asset Value |
173.22 | (13.62) | 29.98 | 56.56 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.08 | 0.04 | 0.02 | (0.02) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.69 | 3.04 | 5.87 | 4.60 | |
Average Payables |
5.26 | 4.83 | 6.20 | 5.83 | |
Average Assets |
785.00 | 692.05 | 690.72 | 767.09 | |
Average Common Equity |
160.02 | 91.51 | 96.07 | 142.28 |
Columns are period end dates